Company / Shareholders' Equity
Ligand Pharmaceuticals, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.0B
FY2025
5-year range
$597.5M / $1.0B
FY2021-FY2025
Trend
+22.5%
vs FY2024
Sector context
#47 of 213
Health Care
What the data says
Ligand Pharmaceuticals, Inc.'s shareholders' equity of $1.0B is higher than 78% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 3 consecutive years, from $597M in FY2022 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +7.5%. Top quartile in the Health Care sector.
Improved from $701M to $1.0B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +19.4%
- 5-Year CAGR
- +7.5%
- 10-Year CAGR
- -
Sector benchmark
-60.1% below sector average
Key checks
Key Insights
- Ligand Pharmaceuticals, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +7.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 22.5% year-over-year.
- Ranks #47 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | +22.5% |
| FY2024 | $830.4M | +18.5% |
| FY2023 | $700.9M | +17.3% |
| FY2022 | $597.5M | -27.2% |
| FY2021 | $821.2M | +15.7% |
| FY2020 | $709.5M | -7.5% |
| FY2019 | $767.2M | +36.8% |
| FY2018 | $560.9M | +40.3% |
| FY2017 | $399.8M | +17.1% |
| FY2016 | $341.3M | +43.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026